• Mashup Score: 0

    Announced on July 17, 30-month data from the ATTRibute-CM trial provide the most comprehensive insight yet into the long-term effects of acoramidis use in patients with transthyretin amyloid cardiomyopathy.

    Tweet Tweets with this article
    • Earlier today, @BridgeBioPharma announced positive 30-month data from part B of the ATTRibute-CM trial. Learn more about results from the phase 3 trial, which will be used in an NDA submission expected by the end of 2023: https://t.co/7gpchWyjRB #Cardiotwitter #Cardiomyopathy

  • Mashup Score: 0

    Mona Shahriari, MD, reviews the efficacy data of topical treatments in the treatment of plaque psoriasis, and Linda Stein Gold, MD, discusses unmet needs in the plaque psoriasis treatment landscape.

    Tweet Tweets with this article
    • Hear our panel of experts review efficacy data of topical treatments for #PlaquePsoriasis and discuss unmet needs in the current treatment landscape: https://t.co/Ow0WQ9cbFd #Dermatology https://t.co/baDucL5AyL

  • Mashup Score: 0

    Arthralgia is the precursor to rheumatoid arthritis for many patients. How much do you know about identifying patients with clinically suspect arthralgia? Test your knowledge with this quiz.

    Tweet Tweets with this article
    • Is the following statement true or false? The American College of #Rheumatology has identified 7 clinical parameters to define clinically suspect arthralgia: https://t.co/XYLOBrA1Fo #RheumatoidArthritis

  • Mashup Score: 0

    The latest episode of New Insight with Veeral Sheth, MD features an insightful conversation with David Eichenbaum, MD on his goals in mentoring the next generation of retina specialists, sharing anecdotes about his own journey in ophthalmology.

    Tweet Tweets with this article
    • Looking for something to do this weekend? Listen to the latest episode of our ophthalmology podcast #NewInsight on mentorship and the future of #retina Click here: https://t.co/DmW7kSnpRK https://t.co/QRXCUOLj5I